Dr. Reddy’s Laboratories Ltd. has announced the launch of Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Durezol (Difluprednate Ophthalmic Emulsion 0.05%) in the US market, following the approval by the US Food and Drug Administration (USFDA).

The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA.

Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05% is available in 5 ml bottles in case packs of 24.

Established in 1984, Dr. Reddy's Laboratories Ltd. are committed to providing access to affordable and innovative medicines. Driven by the purpose of ‘Good Health Can’t Wait’, the company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.

The company's major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. The company's current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.